Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
24 Luglio 2023 - 12:30PM
Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage
biopharmaceutical company developing a new class of
complement-based medicines for patients with classical
complement-mediated autoimmune, neurodegenerative and ophthalmic
disorders, today announced the company will present results from
the ongoing ARCHER Phase 2 trial in patients with geographic
atrophy (GA) at the American Society of Retina Specialists (ASRS)
2023 Annual Meeting taking place July 28 – August 1, 2023 in
Seattle.
Details of the presentation are as follows:
- Date and Time: Sunday, July 30, 2023 at 9:00
a.m. PT
- Title: Treatment of Geographic Atrophy
Secondary to Age-Related Macular Degeneration with Intravitreal
ANX007: Results of the ARCHER Study
- Presenter: Jeffrey S. Heier, M.D., Director of
the Retina Service and Retina Research, Ophthalmic Consultants of
Boston, and an investigator in ARCHER
- Session: Dry AMD Symposium 2
Conference Call InformationAnnexon management
will host a conference call, joined by Dr. Heier, on Monday, July
31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET. The webcast and
accompanying slides will be available under the ‘Events &
Presentations’ section on the Investors & Media page at
www.annexonbio.com. A replay of the webcast will be archived on the
Annexon website for 30 days. Dial-in information for conference
participants may be obtained by registering for the event here.
About AnnexonAnnexon (Nasdaq: ANNX) is a
clinical-stage biopharmaceutical company seeking to bring
game-changing medicines to patients with classical
complement-mediated diseases of the body, brain and eye. The
classical complement pathway within the immune system, when
overactivated, drives inflammation in a host of autoimmune,
neurodegenerative and ophthalmic diseases. Annexon is advancing a
new class of complement medicines targeting the early classical
cascade and all downstream pathway components that contribute to
disease, while selectively preserving the beneficial immune
functions of other complement pathways. Annexon is rigorously
developing a pipeline of diversified product candidates across
multiple mid- to late-stage clinical trials, with clinical data
anticipated throughout 2023 and beyond.
Contacts: Investors:Chelcie ListerTHRUST
Strategic Communicationschelcie@thrustsc.com
Media:Sheryl SeapyReal
Chemistry949-903-4750sseapy@realchemistry.com
Grafico Azioni Annexon (NASDAQ:ANNX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Annexon (NASDAQ:ANNX)
Storico
Da Giu 2023 a Giu 2024